To estimate the extent of cross‐protective immunity following COVID‐19 booster vaccination, we measured the concentration of IgG antibodies to spike protein (anti‐S IgG) and NAb titers from HCWs and elderly subjects sampled ≥21 days after the third vaccine dose (Fig. 1, Table 1). The gene discussed is CHMP5; the disease is COVID-19.